Abbott India Ltd. (BSE: 500488) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹55,577 Cr, it ranks #189 by market cap among the 6,137 Indian listed companies on FinBizNet, and #1 of 63 in Pharmaceuticals. At ₹25,030.00 (as of 25 Oct 2026), the share price is 18.3% below its 52-week high of ₹30,655.00 and 1.5% above its 52-week low of ₹24,650.00. The share price is down 16.1% over one year and down 10.6% over three months.
| Current Price | ₹25,030.00 |
|---|---|
| Market Cap | ₹55,577 Cr |
| BSE Code | 500488 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 35.5 |
| Return on Equity | 34.46% |
| Return on Assets | 18.28% |
| 52-Week Range | ₹24,650.00 – ₹30,655.00 |
| 1-Year Price Change | -16.1% |
| 3-Month Price Change | -10.6% |
| Beta (1Y) | -0.17 |
| Dividend Yield | 2.03% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.abbott.co.in |
| Revenue | ₹1,814 Cr |
|---|---|
| Net Profit | ₹429 Cr |
| Net Margin | 23.6% |
| EPS (Basic) | ₹201.66 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women’s health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
1. Pharmaceuticals-This segment offers pharmaceutical products. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines, consumer health, etc.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,915 Cr | 80.6 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Abbott India Ltd. is trading at ₹25,030.00, with a market capitalisation of ₹55,577 Cr.
Abbott India Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Abbott India Ltd. has a P/E of 35.5 and a return on equity of 34.46%.
Abbott India Ltd. is listed on the BSE under the scrip code 500488.
Abbott India Ltd.'s share price is down 16.1% over one year and down 10.6% over three months. Its 52-week range is ₹24,650.00 to ₹30,655.00.
In Q1 FY27, Abbott India Ltd. reported revenue of ₹1,814 Cr and net profit of ₹429 Cr, with basic EPS of ₹201.66 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.